SEC Form 4 · accession 0001969082-26-000009
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeff Cislini
Officer — SVP & General Counsel
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 6:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 16, 2026 | S | 52 | $195.0087 | D | 55,855 | D | |
| Common StockF3 | Sep 16, 2026 | S | 3,314 | $199.3032 | D | 52,541 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
- F2The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 37,088 restricted stock units.